Phase II Evaluation of Dalantercept in the Treatment of Persistent or Recurrent Epithelial Ovarian Cancer: an NRG Oncology/Gynecologic Oncology Group Study

OBJECTIVE: To determine the efficacy of dalantercept, a soluble ALK1 inhibitor receptor fusion protein, in patients with persistent or recurrent ovarian carcinoma and related malignancies METHODS: Eligibility criteria included measurable disease, 1-2 prior cytotoxic regimens and GOG performance stat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Gynecol Oncol
Autores principales: Burger, Robert A., Deng, Wei, Makker, Vicky, Collins, Yvonne, Gray, Heidi, Debernardo, Robert, Martin, Lainie P., Aghajanian, Carol
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6546175/
https://ncbi.nlm.nih.gov/pubmed/30041929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.06.017
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares